Active, not recruitingPhase 2NCT06607016
A Clinical Trial With KJ103 in Anti-GBM Disease
Studying Anti-glomerular basement membrane disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.
- Intervention
- KJ103 for Injection(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- Peking University First Hospital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06607016 on ClinicalTrials.govOther trials for Anti-glomerular basement membrane disease
Additional recruiting or active studies for the same condition.
See all trials for Anti-glomerular basement membrane disease →